Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma

Molecular Cancer Therapeutics
Parag P PatwardhanGary K Schwartz

Abstract

Sarcomas are rare cancers that make up about 1% of all cancers in adults; however, they occur more commonly among children and young adolescents. Sarcomas are genetically complex and are often difficult to treat given the lack of clinical efficacy of any of the currently available therapies. Receptor tyrosine kinases (RTK) such as c-Kit, c-Met, PDGFR, IGF-1R, as well as FGFR have all been reported to be involved in driving tumor development and progression in adult and pediatric soft-tissue sarcoma. These driver kinases often act as critical determinants of tumor cell proliferation and targeting these signal transduction pathways remains an attractive therapeutic approach. Nintedanib, a potent triple angiokinase inhibitor, targets PDGFR, VEGFR, and FGFR pathways critical for tumor angiogenesis and vasculature. In this study, we evaluated the preclinical efficacy of nintedanib in soft-tissue sarcoma cell lines. Nintedanib treatment resulted in significant antiproliferative effect in vitro in cell lines with high expression of RTK drug targets. Furthermore, treatment with nintedanib showed significant downregulation of downstream phosphorylated AKT and ERK1/2. Finally, treatment with nintedanib resulted in significant tumor growt...Continue Reading

References

Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jan 11, 2003·Science·Michael C HeinrichJonathan A Fletcher
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S Daugaard
Mar 30, 2005·Expert Opinion on Drug Safety·Robin L Jones, Ian R Judson
Apr 9, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tatsuya IshibeJunya Toguchida
Aug 19, 2005·The New England Journal of Medicine·Matthew A ClarkJ Meirion Thomas
Sep 27, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Batya BarkanYoel Kloog
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rashmi ChughLaurence H Baker
Jul 7, 2010·Cell·Mark A Lemmon, Joseph Schlessinger
Sep 18, 2010·Expert Opinion on Investigational Drugs·Sumanta Kumar PalRobert A Figlin
May 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keila E TorresDina Lev
Oct 26, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan L Ho, Gary K Schwartz
Nov 2, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jilong YangWei Zhang
Jun 30, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael C HeinrichMaria Debiec-Rychter
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A DicksonGary K Schwartz
May 18, 2013·EMBO Molecular Medicine·Ariadna Mendoza-NaranjoPoul H Sorensen
Nov 12, 2014·Expert Opinion on Investigational Drugs·Kristen Keon Ciombor, Tanios Bekaii-Saab
Dec 5, 2014·Journal of Medicinal Chemistry·Gerald J RothRolf Kaiser
Jul 28, 2016·Cancer Biology & Medicine·Wen-Ya ZhouJi-Long Yang

❮ Previous
Next ❯

Citations

Nov 2, 2019·Expert Review of Anticancer Therapy·Christopher P WildingPaul H Huang
Mar 4, 2021·Cell Proliferation·Guihong LiuXiawei Wei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.